quinoxalines has been researched along with Anxiety Neuroses in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alyaeva, AG; Gudasheva, TA; Koliasnikova, KN; Povarnina, PY; Seredenin, SB; Vorontsova, ON | 1 |
| Ditre, JW; Farris, SG; Leventhal, AM; Schmidt, NB; Zvolensky, MJ | 1 |
| Benjamin, D; Lal, H; Meyerson, LR | 1 |
3 other study(ies) available for quinoxalines and Anxiety Neuroses
| Article | Year |
|---|---|
The Anxiolytic Effect of the Neuropeptide Cycloprolylglycine Is Mediated by AMPA and TrkB Receptors.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain-Derived Neurotrophic Factor; Carbazoles; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Indole Alkaloids; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Peptides, Cyclic; Protein-Tyrosine Kinases; Quinoxalines; Receptors, AMPA | 2020 |
Emotional disorders and smoking: relations to quit attempts and cessation strategies among treatment-seeking smokers.
Topics: Adult; Anxiety Disorders; Benzazepines; Bupropion; Cross-Sectional Studies; Depressive Disorder; Dopamine Uptake Inhibitors; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2015 |
The effects of 5-HT1B characterizing agents in the mouse elevated plus-maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Chlordiazepoxide; Male; Mice; Mice, Inbred Strains; Models, Psychological; Pentylenetetrazole; Piperazines; Quinoxalines; Serotonin | 1990 |